The Differential Influence of Cold Ischemia Time on Outcome After Liver Transplantation for Different Indications—Who Is at Risk? A Collaborative Transplant Study Report

Frontiers in Immunology

Volumn 11, Issue , 2020, Pages

  Lozanovski, Vladimir J ^a,b   Döhler, Bernd ^a   Weiss, Karl Heinz ^a,b   Mehrabi, Arianeb ^a,b   Süsal, Caner ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CIT; cold ischemia time; collaborative transplant study; CTS; EDC; extended donor criteria; liver transplantation; outcome

Indexed keywords

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL OUTCOME; COLD ISCHEMIA; END STAGE LIVER DISEASE; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RISK FACTOR; ADOLESCENT; ADVERSE EVENT; CLASSIFICATION; GRAFT RECIPIENT; GRAFT REJECTION; INTERSECTORAL COLLABORATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COLD ISCHEMIA; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INTERSECTORAL COLLABORATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 85085325813     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2020.00892     Document Type: Article

References (27)

1. Bruns H, Lozanovski VJ, Schultze D, Hillebrand N, Hinz U, Büchler MW, et al. Prediction of postoperative mortality in liver transplantation in the era of MELD-based liver allocation: a multivariate analysis. PLoS ONE. (2014) 9:e98782. 10.1371/journal.pone.009878224905210
2. Lozanovski VJ, Khajeh E, Fonouni H, Pfeiffenberger J, von Haken R, Brenner T, et al. The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation. Langenbecks Arch Surg. (2018) 403:719–31. 10.1007/s00423-018-1704-z30112639
3. Pinna AD, Yang T, Mazzaferro V, De LC, Zhou J, Roayaie S, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular Carcinoma. Ann Surg. (2018) 268:868–75. 10.1097/SLA.000000000000288930080736
4. Eurotransplant. Available online at: https://www.eurotransplant.org/cms/index.php?page=newsitems (accessed on 14 December, 2019).
5. Lozanovski VJ, Kerr LT, Khajeh E, Ghamarnejad O, Pfeiffenberger J, Hoffmann K, et al. Liver grafts with major extended donor criteria may expand the organ pool for patients with hepatocellular Carcinoma. J Clin Med. (2019) 8:1692. 10.3390/jcm810169231618968
6. Adam R, Cailliez V, Majno P, Karam V, McMaster P, Calne RY, et al. Normalised intrinsic mortality risk in liver transplantation: European liver transplant registry study. Lancet. (2000) 356:621–7. 10.1016/S0140-6736(00)02603-910968434
7. Silberhumer GR, Rahmel A, Karam V, Gonen M, Gyoeri G, Kern B, et al. The difficulty in defining extended donor criteria for liver grafts: the eurotransplant experience. Transplant Int. (2013) 26:990–8. 10.1111/tri.1215623931659
8. Houben P, Döhler B, Weiß KH, Mieth M, Mehrabi A, Süsal C. Differential influence of donor age depending on the indication for liver transplantation–a collaborative transplant study report. Transplantation. (2020) 104:779–87. 10.1097/TP.000000000000297032224813
9. Adam R, Karam V, Cailliez V, O Grady JG, Mirza D, Cherqui D, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)−50-year evolution of liver transplantation. Transplant Int. (2018) 31:1293–317. 10.1111/tri.1335830259574
10. Kim W, Lake JR, Smith J, Schladt D, Skeans M, Noreen S, et al. OPTN/SRTR 2017 annual data report: liver. Am J Transplant. (2019) 19(Suppl. 2):184–283. 10.1111/ajt.1527630811890
11. Opelz G, Döhler B, Ruhenstroth A, Cinca S, Unterrainer C, Stricker L, et al. The collaborative transplant study registry. Transplant Rev. (2013) 27:43–5. 10.1016/j.trre.2013.01.00423465693
12. Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. J Hepatol. (2018) 70:745–58. 10.1016/j.jhep.2018.12.00930576701
13. Feng S, Lai JC. Expanded criteria donors. Clin Liver Dis. (2014) 18:633–49. 10.1016/j.cld.2014.05.00525017080
14. Pratschke S, Bender A, Boesch F, Andrassy J, van Rosmalen M, Samuel U, et al. Association between donor age and risk of graft failure after liver transplantation: an analysis of the Eurotransplant database. Transplant Int. (2019) 32:270–9. 10.1111/tri.1335730260509
15. Paterno F, Wima K, Hoehn RS, Cuffy MC, Diwan TS, Woodle SE, et al. Use of elderly allografts in liver transplantation. Transplantation. (2016) 100:153–8. 10.1097/TP.000000000000080626154390
16. Briceno J, Ciria R, Pleguezuelo M, Naranjo A, Sanchez-Hidalgo J, Ruiz-Rabelo J, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc. (2007) 39:2297–9. 10.1016/j.transproceed.2007.07.06917889169
17. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transplant. (2006) 12:134–9. 10.1002/lt.2058316382465
18. Briceño J, Marchal T, Padillo J, Solórzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation. (2002) 74:522–6. 10.1097/00007890-200208270-0001512352912
19. Gonzalez SA. Management of recurrent hepatitis C following liver transplantation. Gastroenterol Hepatol. (2010) 6:637–45. 21103443
20. Vinaixa C, Rubín A, Aguilera V, Berenguer M. Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol. (2013) 26:304–13. 24714603
21. Unterrainer C, Opelz G, Döhler B, Süsal C. Pretransplant cancer in kidney recipients in relation to recurrent and de novo cancer incidence posttransplantation and implications for graft and patient survival. Transplantation. (2019) 103:581–7. 10.1097/TP.000000000000245930418430
22. Goldaracena N, Quinonez E, Mendez P, Anders M, Ganem FO, Mastai R, et al. Extremely marginal liver grafts from deceased donors have outcome similar to ideal grafts. Transplant Proc. (2012) 44:2219–22. 10.1016/j.transproceed.2012.07.11322974958
23. Kwong A, Kim WR, Mannalithara A, Heo NY, Udompap P, Kim D. Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. Liver Transplant. (2018) 24:735–43. 10.1002/lt.2497329125676
24. Yi Z, Mayorga ME, Orman ES, Wheeler SB, Hayashi PH, Barritt TA. Trends in characteristics of patients listed for liver transplantation will lead to higher rates of waitlist removal due to clinical deterioration. Transplantation. (2017) 101:2368–74. 10.1097/TP.000000000000185128858174
25. Braat A, Blok J, Putter H, Adam R, Burroughs A, Rahmel A, et al. The eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant. (2012) 12:2789–96. 10.1111/j.1600-6143.2012.04195.x22823098
26. Feng S, Goodrich N, Bragg-Gresham J, Dykstra D, Punch J, DebRoy M, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. (2006) 6:783–90. 10.1111/j.1600-6143.2006.01242.x16539636
27. Mossdorf A, Kalverkamp S, Langenbrinck L, Ulmer TF, Temizel I, Neumann U, et al. Allocation procedure has no impact on patient and graft outcome after liver transplantation. Transplant Int. (2013) 26:886–92. 10.1111/tri.1214423834494